Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany
Autor: | Brenda Bongaerts, Bianca Kollhorst, Oliver Kuss, Iris Pigeot, Wolfgang Rathmann |
---|---|
Rok vydání: | 2021 |
Předmět: |
Data Analysis
Male Dipeptidyl-Peptidase IV Inhibitors Endocrinology Diabetes and Metabolism General Medicine Middle Aged Glucagon-Like Peptide-1 Receptor Metformin Insurance Glucose Sulfonylurea Compounds Endocrinology Diabetes Mellitus Type 2 Internal Medicine Humans Hypoglycemic Agents Female Sodium-Glucose Transporter 2 Inhibitors Aged |
Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 130:587-595 |
ISSN: | 1439-3646 0947-7349 |
Popis: | Aims To describe dispensation patterns of glucose-lowering drugs in newly diagnosed type 2 diabetes in Germany. Materials and methods Based on claims data from four statutory health insurances (German Pharmacoepidemiological Research Database,>25 million insurants), all individuals with newly diagnosed type 2 diabetes were identified. Eligible patients had a first diagnosis for type 2 diabetes between January 2012 and December 2016. We analyzed the dispensation patterns of first-line glucose-lowering therapies initiated in the year after diabetes diagnosis and patterns of second-line therapies dispensed one year after first-line treatment. Results A total of 356,647 individuals with newly diagnosed type 2 diabetes were included (average age [SD]: 63.5 [13.4] years; 49.3% males). Of the 31.6% of individuals who were pharmacologically treated in the year after diagnosis, metformin monotherapy was most frequently dispensed (73.1%), followed by dual therapy of metformin and dipeptidyl peptidase-4 inhibitors (DPP-4is) (6.4%), and monotherapy with DPP-4is (2.9%). From 2012 through 2016, sulfonylurea dispensations were reduced by more than 50%. Dispensations for combination therapies with DPP-4is increased up to 10.6%. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors contributed to 2% of all treatments. After a median of 5 months, 20.0% of individuals on pharmacological therapy initiated second-line glucose-lowering treatment. Conclusions Data from German statutory health insurances (2012 to 2016) showed that most individuals with newly diagnosed type 2 diabetes were dispensed metformin monotherapy in line with diabetes care guidelines. A substantial decrease in the use of sulfonylureas was observed after the introduction of DPP-4i and GLP-1 receptor agonists. |
Databáze: | OpenAIRE |
Externí odkaz: |